-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on ResMed, Raises Price Target to $270

Benzinga·10/30/2026 20:37:28
Listen to the news
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Neutral and raises the price target from $240 to $270.